A new study presented at the 2013 European Cancer Congress (ECC2013) reveals that using monoclonal antibody ipilimumab in treating patients with advanced melanoma can increase their survival period up to 10 years. Professor Stephen Hodi (MD), Assistant Professor of Medicine at the Dana-Farber Cancer Institute (Boston, USA), told the congress: "Our findings demonstrate that there is a plateau in overall survival, which begins around the third year and extends through ...
via Medindia Health News
More READ
No comments:
Post a Comment